Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2025—Diasorin has received FDA 510(k) clearance for the Simplexa COVID-19/Flu A/B and RSV Direct kit, a sample-to-answer test for the detection of SARS-CoV-2, influenza A and B virus, and respiratory syncytial virus directly from nasopharyngeal and nasal swab specimens. The kit runs on the Liaison MDX system and provides differential detection in about 45 minutes.
December 2025—The Journal of Clinical Microbiology has published an article describing ARUP Laboratories’ validation of a deep convolutional neural network to detect parasites in concentrated wet mounts of stool.
December 2025—Smart In Media has released version 3.2 of its PathoZoom Scan and LiveView. The new version includes enhancements to workflow, image transmission, and LIS integration.
December 2025—Qiagen has entered into a definitive agreement to fully acquire Parse Biosciences, a provider of scalable, instrument-free solutions for single-cell research, for $225 million. The acquisition will expand Qiagen’s Sample technologies portfolio into the single-cell sequencing market with highly scalable chemistry designed to power research involving millions of billions of cells, according to a press release from Qiagen. Parse’s scalable chemistry is also expected to accelerate growth in Qiagen’s digital insights bioinformatics business.
December 2025—The FDA has approved QuidelOrtho Corp.’s Micro Typing Systems DAT card, a gel-based solution for direct antiglobulin testing, and the Ortho Vision platform, an automated blood testing system.
December 2025—The Food and Drug Administration has granted expanded clearance for use of the FecalSwab sample type across all Qiagen QIAstat-Dx gastrointestinal panels, enabling full pathogen detection, including of Shiga toxin–producing E. coli and enteropathogenic E. coli. STEC and EPEC can now be reported when testing by FecalSwab collected from stool samples with the QIAstat-Dx Gastrointestinal Panel 2, including detection of clinically relevant STEC subtypes such as stx2f. STEC can now also be reported for the QIAstat-Dx GI Panel 2 Mini B and QIAstat-Dx GI Panel 2 Mini B&V.
December 2025—Proscia is introducing virtual staining, powered by Pictor Labs, to its Concentriq software platform to help laboratories reduce the costs associated with traditional chemical methods and drive efficiency in high-throughput workflows. Virtual staining uses AI models to replicate the effects of stains on tissue images. These models can generate a whole slide virtually stained image from label-free inputs in a few minutes. The company will integrate a menu of H&E, immunohistochemical, and special stains into Concentriq.
December 2025—GSI Group Holdings has acquired GenesisBPS, a designer and manufacturer of specialized benchtop blood processing equipment and laboratory consumables. GSI Group provides a wide range of laboratory single-use products, benchtop instruments, and related accessories and has locations across the U.S., Europe, and Asia. GenesisBPS joins GSI Group brands Globe Scientific, AmScope, Euromex, and Physix, among others.
November 2025—Bio-Rad Laboratories launched Specialty Immunoassay Plus in Europe, a comprehensive immunoassay quality control product for specialty immunoassay testing procedures.
November 2025—The FDA granted breakthrough therapy designation to Ifinatamab deruxtecan for treating extensive-stage small cell lung cancer after platinum-based chemotherapy.
